-
Mashup Score: 104
Responses to first-line PD-1 inhibition vary among patients with metastatic non-small cell lung cancer (NSCLC) and a PD-L1 TPS ≥50%. We previously reported improved clinical outcomes to first-line PD-1 inhibition in patients with metastatic NSCLC with a PD-L1 TPS of ≥90% vs 50-89% in a pilot study. Here, we report the three-year survival with first-line pembrolizumab and cemiplimab in two large independent cohorts of patients with PD-L1 TPS ≥90% vs 50-89% and characterize genomic and immunophenotypic differences between these PD-L1 expression groups, which were largely unknown.
Source: www.jtocrr.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 45Brief Report: Real-World Efficacy and Safety of Sotorasib in U.S. Veterans with KRAS G12C-Mutated Non-Small Cell Lung Cancer - 1 month(s) ago
The KRAS G12C inhibitor sotorasib was approved for the treatment of advanced NSCLC in the second line or later based on the CodeBreaK100 trial. However, data on the real-world efficacy and safety of sotorasib, as well as its optimal dose, remain limited.
Source: www.jtocrr.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 19Harnessing Opportunity: Pilot Intervention to Improve Lung Cancer Screening for Women Undergoing Breast Screening Mammography - 1 month(s) ago
The screening mammogram could be a “teachable moment” to improve lung cancer screening (LCS) uptake. The aim of our project was to combine patient self-referral with eligibility identification by providers as a two-pronged approach to increase rates of LCS among eligible women.
Source: www.jtocrr.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 61
MET proto-oncogene (MET) alterations are known driver oncogenes in non-small cell lung cancer (NSCLC). Since the identification of MET as a potential therapeutic target, extensive clinical trials have been performed. As a result, MET-targeted therapies, including MET tyrosine kinase inhibitors, monoclonal antibodies, and MET antibody–drug conjugates, now play important roles in the standard treatment of MET-altered NSCLC; they have considerably improved the outcomes of patients with tumors that harbor MET oncogenic drivers.
Source: www.jtocrr.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 97
The identification of genomic ‘targets’ through next-generation sequencing (NGS) of patient’s NSCLC tumors has resulted in a rapid expansion of targeted treatment options for selected patients. This retrospective study aims to identify the proportion of patients with advanced NSCLC in the Republic of Ireland whose tumours harbour actionable genomic alterations via broad NGS panel testing.
Source: www.jtocrr.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 57Brief report: Long-term follow-up of adjuvant pembrolizumab following locally ablative therapy for oligometastatic non-small cell lung cancer. - 1 month(s) ago
Patients with oligometastatic non-small cell lung cancer (NSCLC) benefit from locally ablative therapies (LAT); the role of adjuvant systemic therapies, however, remains less clear. In a single-arm Phase II clinical trial, we demonstrated that patients with oligometastatic NSCLC treated with a year of pembrolizumab following LAT had superior progression free survival (PFS) compared to a historical control cohort. Herein, we present long term follow-up on PFS and overall survival (OS).
Source: www.jtocrr.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 83Detection of tumor DNA in bronchoscopic fluids in peripheral non small cell lung cancer: a proof-of-concept study - 1 month(s) ago
The detection of tumor DNA in the supernatant of guide sheath flush fluid collected during r-EBUS bronchoscopy represents a sensitive and complementary method for genotyping non-small cell lung cancer.
Source: www.jtocrr.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 2
We evaluated efficacy and safety of cabozantinib plus atezolizumab or cabozantinib alone in advanced non-small cell lung cancer (NSCLC) previously treated with an immune checkpoint inhibitor (ICI).
Source: www.jtocrr.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 47Real World Treatment and Outcomes in ALK-rearranged Non-small Cell Lung Cancer; Results from a Large US-based Database - 2 month(s) ago
Anaplastic Lymphoma Kinase (ALK)-rearranged advanced non-small cell lung cancer (aNSCLC) represents 4% of all NSCLC, and multiple ALK-targeted therapies (ALK-inhibitors) are now available for use. Little is known about changes in treatment patterns, or how prognostic factors and sequence of therapy may impact overall survival in the real-world setting. We aim to describe initial and subsequent treatments used, survival outcomes, prognostic factors and the impact of treatment on overall survival in the largest (N= 739) real-world cohort of patients with ALK+ aNSCLC reported in the literature.
Source: www.jtocrr.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 39
Both sotorasib and adagrasib are approved for use in metastatic KRASG12C -mutated NSCLC after cancer progression on chemotherapy and immunotherapy. Hepatoxicity is a commonly encountered side effect of both agents, and little data exists about the safety of sequential use of these agents if hepatotoxicity is encountered. In this case report, we describe a patient who developed recurrent hepatotoxicity with sotorasib and was able to switch to adagrasib without hepatotoxicity and subsequently experienced prolonged cancer response.
Source: www.jtocrr.orgCategories: General Medicine News, Hem/OncsTweet
Among PDL1 high NSCLC, PFS and OS better with PDL1 ≥90% compared to 50-89%, report @JTOonline. Seen with 1L pembrolizumab (PFS HR 0.69, OS HR 0.70) and cemiplimab in EMPOWER-Lung 1 (PFS HR 0.53, OS HR 0.63). PDL1 50-80% enriched for STK11 and SMARCA4 mt https://t.co/I10meOknWR